1. FDA. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. Office of Communications US FDA UCM291134, pp 1–20; 2015.
2. FDA. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Office of Communications US FDA UCM291128, pp 1–25; 2015.
3. FDA Biosimilars: additional questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Office of Communications US FDA UCM273001, pp 1–14; 2015.
4. FDA. FDA briefing document oncologic drugs advisory committee meeting: BLA 125553 EP2006, a proposed biosimilar to Neupogen® (filgrastim). Office of Communications US FDA UCM428780, pp 1–62; 2015.
5. Kozlowski S. US FDA perspectives on biosimilar biological products, In 2014 Biotechnology Technology Summit. Rockville: IBBR University of Maryland; 2014.